Dacarbazine for injection 600 mg/vial, BP - Discoloration after reconstitution of vials

Following the receipt of customer reports, Hospira Healthcare Corporation, in consultation with Health Canada, is informing Healthcare professionals that some vials of Dacarbazine for Injection 600 mg/vial, BP may turn pink immediately after reconstitution or during storage of reconstituted product. Dacarbazine for Injection is indicated as palliative therapy for metastatic malignant melanoma. Read more here.